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Development ofapproaches torisk assessment for reproductive toxicity has aided in the critical evaluation
ofthe scientific basis for interpretation ofdataandthe description ofassumptions underlyingthe process. In
addition, ithashelpedtostandardize, totheextentpossible,the use ofqualitative andquantitativedatainthe
hazard identification anddose-response processes andto identify research neededto fill gaps in the available
database. The standard study protocols for evaluating reproductive and developmental hazards include
developmental toxicity studies and both short-term and longer-term reproductive studies. These study
protocols have been in use for several decades, but development ofrisk assessment approaches has prompted
the recommendation ofadditional end point measures to these protocols. These include evaluation ofspecific
neurologic and behavioral function of offspring following prenatal and postnatal exposure, evaluation of
sperm production and quality, reproductive organ weights, and more in-depth testicular histopathology in
males, as well as measures of age at vaginal opening, vaginal cytology, oocyte toxicity, time to mating,
gestation length, and reproductive organ weights in females. Current approaches to risk assessment in
reproductive toxicity involve the determination of a no-observed-adverse-effect level (NOAEL) and the
application ofuncertainty factors (UFs) to account for differences between the experimental animal species
and humans,variability in sensitivity within the human population, and other factors as necessary to derive
the reference dose (RID),-or a specified RfD for developmental toxicity to account for the short period of
exposurerequired. RecognizedlimitationstotheNOAEL/UF approach forcalculatingthe RfDhaveprompted
theinvestigationofalternativeapproaches,suchasthebenchmarkdoseapproach,whichusesmoreofthedata
and takes into consideration the slope ofthe dose-response curve and thevariability in the data. Research to
improve risk assessment for reproductive toxicity is needed in a number of areas, particularly improved




and interpreting data for reproductive toxicity has been
realized within the past few years. Although standard
studies on the reproductive and developmental effects of
chemicals have been conducted and used for regulatory
purposes since the early 1960s (and to a limited extent,
even earlier), onlywithin the last decade have efforts been
made to critically evaluate the scientific basis for inter-
pretation of data and to describe the standard assump-
tionsthat aremadeinthe process ofriskassessment. This
evaluation has also had an impact on the evolution of
improvedtestingapproaches andwillcontinuetoinfluence
the design of testing protocols as advances are made in
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addressing uncertainties when estimating the risk of
reproductive toxicity from exposures to humans.
The U.S. Environmental Protection Agency (EPA) has
been instrumental in developing risk assessment guide-
linesformale andfemalereproductive toxicity,whichwere
proposed in 1988 (1,2), and for developmental toxicity, first
published in 1986 (3) with the final publication in 1991 (4).
These guidelines are based on the paradigm for risk
assessmentdescribedoriginallybythe National Research
Council (5), which included four components: hazard iden-
tification, dose-response assessment, exposure assess-
ment, and risk characterization. Some modifications have
been made in the process, which was based primarily on
cancerrisk assessment, to accountfortheassumption ofa
threshold generally made for noncancer health effects,
including reproductive and developmental toxicity. Cur-
rently, the female and male reproductive guidelines are




discuss the end points that are considered adverse effects
forboth human and experimental animal data. Reproduc-C. A. KIMMEL
Table 1. Risk assessment guidelines: definition ofterms.
Reproductive toxicity
The occurrence of adverse effects on the reproductive system that may
resultfromexposure toenvironmental agents. Toxicitymaybeexpressed
as alterations to the reproductive organs and/or the related endocrine
system. Themanifestation ofsuch toxicitymayinclude, butnotbelimited
to, alterations in sexual behavior, onset of puberty, fertility, gestation,
parturition, lactation, pregnancy outcomes, premature reproductive sen-
escence, or modifications in other functions that are dependent on the
integrity ofthe reproductive system.
Developmental toxicity
The occurrence ofadverse effects on the developing organism that may
result from exposure before conception (either parent), during prenatal
development, or postnatally to the time of sexual maturation. Adverse
developmental effects maybe detected at anypoint in the life span ofthe
organism. The major manifestations of developmental toxicity include
death of the developing organism, structural abnormality, altered
growth, and functional deficiency.
tivetoxicityincludes developmentaltoxicityandalsorefers
to effects on the reproductive organs and/or the related
endocrine system of males and females. Developmental
toxicityincludeseffectsonthedevelopingorganismresult-
ingfrom exposure not only duringthe prenatal period but
alsoexposure ofeitherparentbeforematingandpostnatal
exposure from birth to the time of sexual maturation.
Thus, although separate risk assessment guidelines were
written for male and female reproductive toxicity and for
developmental toxicity because of the complexity of the
systems involved, the two are integrallyrelated, such that
reproductive effects in adults mayresult in developmental
effects, and effects on the developing reproductive system
prenatally or early postnatally may result in reproductive
impairment in adulthood. Data onreproduction and devel-
opment are often found in the same studies (both for
human and experimental animal studies) and are usually
evaluated in concert.
The primary advantages ofdeveloping risk assessment
guidance include a) explicitly stating the assumptions
made in the risk assessment process; b) standardizing to
the extent possible the use ofqualitative and quantitative
data in the hazard identification and dose-response pro-
cesses; and c) identifying research needed for reducing
uncertainties and to fill gaps in the available database.
Each ofthesepointswillbe discussed in more detail inthe
following sections.
Assumptions in Reproductive Toxicity
Risk Assessment
The EPA risk assessment guidelines discuss the basic
assumptions that are generally made in the extrapolation
of data from animal studies to humans. Because ofmany
unknowns in the extrapolation process, assumptions must
be made on the relevance of effects in animal studies to
potential human risk. These assumptions are generally
applied in the absence ofdata but do notpreclude further
investigation to support or refute the assumptions made.
The assumptions are listed in Table 2 and provide the
inferential basis forthe approaches taken to reproductive
risk assessment by the EPA.
Table 2. Basic assumptions for reproductive toxicity risk assessment.
An agent that produces an adverse reproductive effect in experimental
animal studies will potentially pose a hazard to humans after sufficient
exposure.
Reproductive effects are generally the same across species except for
pregnancy outcomes, which may vary depending on species-specific
differences in timing of exposure, critical periods, metabolism, develop-
mental patterns, placentation, or mechanism of action.
Allofthefourmanifestations ofdevelopmentaltoxicity(death, structural
abnormalities, growth alterations, andfunctionaldeficits) areofconcern.
The most appropriate species, ifknown, will be used to estimate human
risk; otherwise, the most sensitive species will be used.
Athreshold is generally assumed forthe dose-response curve forrepro-
ductive effects.
First, it is assumed that an agent that produces an
adversereproductiveeffectinexperimental animalstudies
will potentially pose a hazard to humans following suffi-
cient exposure. This assumption is based on the com-
parisons ofdata for known human reproductive toxicants
(6-11),whichindicatethat,ingeneral, experimentalanimal
data are predictive ofreproductive effects in humans.
Because the basic male and female reproductive pro-
cesses are generally similar across species, adverse
reproductiveeffects are assumedgenerallytobethe same
across species. In the case of pregnancy outcomes, how-
ever,itis assumedthatthetypesofadversedevelopmental
effects seenin animal studies arenotnecessarilythe same
as those that may be produced in humans. Every species
may not react in the same way to a given agent during
development, possibly because of species-specific dif-
ferences in critical periods, timing of exposure, metabo-
lism, developmental patterns,placentation, ormechanisms
ofaction. Thus, itis difficultto determinewhichwillbethe
most appropriate species for predicting the specific types
ofeffects seen in humans.
Itisassumedthatallofthefourmanifestations ofdevel-
opmentaltoxicity(death,structuralabnormalities, growth
alterations, and functional deficits) are of concern. The
tendencytoconsideronlymalformations ormalformations
anddeathasendpointsofconcernignoresthebodyofdata
accumulated ontheeffects ofagents ongrowth alterations
andfunctional deficits inhumans andthefactthatthereis
usually at least one experimental species that mimics the
types ofeffects seen in humans.
When sufficientdata are available (e.g.,pharmacokinet-
ics),itis assumedthatthemostappropriate specieswillbe
used to estimate human reproductive risk. In the absence
of such data, the most sensitive species is used, based on
observations thathumans areoften as sensitive ormore so
than the most sensitive animal species tested.
In general, a threshold is assumed for the dose-
response curveforreproductivetoxicants. Thisisbased on
the known capacity of cells, tissues, and organs of the
reproductive system and of the developing organism to
compensate for ortorepairacertain amountofdamage at
the cellular, tissue, or organ level. Furthermore, multiple
insults atthemolecular orcellularlevelmayberequired to




Standard Reproductive Toxicity Testing
Protocols
Although adequate human data are always preferable
for estimating risks ofreproductive effects from environ-
mental exposures, data from reproductive toxicity studies
in laboratory animal species form the primary database
used for risk assessment in this area. The database on
reproductive toxicity also may be enhanced by data from
othertoxicitystudies, aswell asfrompharmacokinetic and
mechanistic studies.
Historically, different testing approaches have been
used for different types of agents. For pharmaceutical
agents, for example, the three-segment design is required
forreproductive toxicitytesting (12). The segment I study
is designed to evaluate fertility and general reproductive
function and to assess potential effects on development of
offspring. The segment II study is the standard teratol-
ogy or developmental toxicity study and is designed to
provide information on effects from exposure ofmaternal
animals during pregnancy. The segment III study pro-
vides an, assessment of peri- and postnatal, taxicity in
exposed dams and their offspring. Recent efforts at inter-
national harmonization of pharmaceutical testing guide-
lines and development of an integrated protocol have
resulted in a much more flexible study design depending
on the intended use of the drug and other data available
(13).
For foods and food additives, a segment II study is
required aswell as acomprehensivemultigeneration study
(14) designed to provide information (directly or indi-
rectly) concerning the effects of a test substance on
gonadal function, estrous cycles, matingbehavior, concep-
tion, parturition, pregnancy outcome, lactation, and post-
natal growth andviability for up to three generations. For
environmental agents, the segment II study and a two-
generation reproduction study (15-17) are required.
Recommended Additions to Standard
Protocols for Reproductive Toxicity
Data from the multigeneration study provide informa-
tion onthe"couple," sinceboth sexes aretreated.Although
the studies are not designed specifically to allow determi-
nation of the affected sex, evaluation of mating pairs or
animals unable to mate successfully may indicate the
gender affected. Multigeneration protocols are relatively
insensitive in detecting effects on fertility. For example,
normal males of most test species produce numbers of
sperm that greatly exceed the minimum requirements for
fertility as evaluated in current protocols (18-20). Reduc-
tions of up to 90% in number ofnormal sperm may occur
without a statistically significant effect on fertility. In
humans, however, sperm counts areclosertothethreshold
for the number of normal sperm needed to ensure full
reproductive competence, and a decrease in number of
normal sperm is more likely to result in altered fertility.
Therefore, several additions and changes to the basic
protocol have been proposed to improve sensitivity and to
allow better interpretation and more specific information
on the gender(s) affected and on the site of action (e.g.,
gonad or pituitary). For example, in the male, sperm
production and sperm quality, reproductive organ
weights, and more in-depth testicular histopathology
could be added.
In the female, the difference in sensitivity between
rodents and humans maynotbe as great as formales, and
an effect on fertility may reflect changes in the estrous
cycle, endocrine function, or oocyte toxicity.Alongmating
period(upto3weeks) allows thepossibilityofmatingover
several estrous cycles in the female, and sensitivity for
detecting an effect on fertility could be improved by limit-
ingthematingperiod.Therelationshipbetweenfertilityin
females and other measures ofreproductive function has
not been tested adequately, however, and measures of
estrous cycle normality and oocyte toxicity should be
included. In addition, potential effects on sexual develop-
ment and reproductive senescence should be evaluated.
Thus, adequate evaluation offemale reproductive toxicity
should include several measures in addition to those usu-
ally obtained, such as age at vaginal opening, vaginal
cytology, oocyte toxicity (destruction of the primary
oocyte population leading to cessation of ovarian
function), time to mating, gestation length, and reproduc-
tive organ weights based on stage ofthe estrous cycle at
necropsy.
Anotherprotocol that provides a more sensitive evalua-
tion of subfertility is the "fertility assessment by contin-
uous breeding" protocol conducted in mice or rats (21-23).
In this study design, mating pairs are cohabitated for 98
days with continuous exposure. Litters are examined and
removed shortly after birth. The number of litters pro-
duced, litter size, weight, and any external abnormalities
are recorded. The last litter produced is raised to adult-
hood, exposureis continued, andifaneffecthasbeen seen,
cross-matingwith control offspringis conducted to deter-
mine which sex is affected. In addition, numerous
reproductiveendpointsareevaluated.Withthisapproach,
each pair may deliver up to five litters in the time period
designated, and the average number of litters per pair
provides an index of fertility or subfertility. This study
design takes less time overall than the multigeneration
study, butprovides additional dataincluding amore sensi-
tive measure ofsubfertility.
Testing Approaches for Evaluating
Functional Developmental Toxicity
The currently available protocols for testing chemicals
in laboratory animals provide limited information on the
hazards of chemical exposure in neonatal and young
animals. In many cases, they could be improved upon to
provide more complete information, such as incorporating
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tests of functional effects of specific organ systems. The
only organ system for which testing guidelines are avail-
ableinsuchtestingprotocolsisthecentral nervoussystem
(CNS).
Although a few countries currently have testing guide-
lines that call for behavioral testing of offspring, EPA is
the onlyregulatory agencywith specifictestingguidelines
thataddress anumberofissues ofprotocoldesign, aspects
ofCNSfunctiontobeincluded, and criteriaforselectionof
testing procedures. The developmental neurotoxicity pro-
tocol (24) for testing pesticides and industrial chemicals
was designed to evaluate potential functional and mor-
phological hazards to the developing nervous system that
may arise in offspring from exposure of the maternal
animal during pregnancy and lactation. It also provides
general information on postnatal growth and survival.
Because of its design, the developmental neurotoxicity
testing protocol may be conducted as a separate study,
concurrently with, or as a follow-up to, a developmental
toxicity (segment II) study, or be folded into a multi-
generation study in the second generation. It is required
on a case-by-case basis depending on what other toxicity
information is available on each chemical orclass ofchemi-
cal. Although the developmental neurotoxicity protocol
was designed to assess specific effects on the developing
nervous system, it could easily be used as a model for
evaluating functional and morphological hazards on other
organ systems. For example, if an agent is suspected of
producing developmental renal toxicity (25,26), the basic
framework of this same study design may be used, with
possible modification of the period and duration of expo-
sure and substitution ofparameters used to assess renal




Current approaches to risk assessment in reproductive
toxicity involve the determination of a no-observed-
adverse-effect level (NOAEL) from standard studies with
aminimal dataset(usuallythree doselevels and acontrol).
Uncertainty factors (UFs) are then applied to account for
differences between the experimental animal species and
humans, variability in sensitivity within the human popu-
lation, and other factors as necessary to derive the refer-
ence dose (RfD). Aspecific RfD for developmental toxicity
(RfDDT)is determined to account for the short period of
exposure required. The RfD is expressed in terms of the
exposure duration, route, and timing of exposure. In the
case of inhalation exposure, a reference concentration
(RfC) is determined. The RfD is assumed to represent a
dose atwhich no excess risk forreproductive effects above
background are likely to occur in the human population.
There are several limitations to the NOAEL/UF
approach for calculating the RfD: a) use of the NOAEL
focuses only on the dose that is the NOAEL; in fact, the
NOAEL must be one ofthe experimental doses; b) use of
theNOAELignoresthe shapeofthedose-response curve;
c) this approach results in smaller studies having higher
NOAELs because datavariance is not taken into account;
d) the NOAEL approach does not result in an estimate of
risk at a given dose, especially above the RfD.
The benchmark dose approach was originally proposed
in 1984 by Crump (28) as a simple but important improve-
ment in the estimation ofthe RfD. As shown in Figure 1,
the benchmark dose is the lower confidence limit on an
effective dose (LED) corresponding to an increase in the
incidence of an effect at a particular risk level, e.g., the
LED10 is the lower confidence limit on a dose that is
effective in producing a 10% increase in response. Uncer-
taintyfactors may then be applied to the LED10 to calcu-
late the RfD. Since the NOAEL theoretically can fall
anywhere between zero and an incidence just below that
detectable as an increase above control levels (usually in
the range of7-10% for quantal data), the benchmark dose
wouldprovide acommon startingpointforapplyinguncer-
taintyfactors andwouldresultin RfDswithmore compar-
able levels of protection than when NOAELs are used.
Which benchmark dose to use is still under consideration.
Crump (28) and Kimmel and Gaylor (29) discussed theuse
oftheLED1obecauseitusuallyfallswithintheexperimen-
tal range. Ifenough data are available at the lower end of
the dose-response range, itis also possible to calculate an
LED05oranLEDO1 [asdiscussedbyGaylor(30)and Chen
and Kodell (31)], values that would be closer to a true
NOAELandthatwouldrequire applicationoffeweruncer-
tainty factors than the LED0.
Various mathematical models have been proposed for
use in the benchmark dose approach. Theoretically, the
choice ofthe model should not be critical as long as it fits
the data well because estimation is within the observed
Excess Upper confidence









0 LED /UF LED0 ED,0
(RfD orRfD101 (BD)
DOSE (d)
FIGURE 1. Graphic illustration of the benchmark dose approach. The
benchmark dose (BD) approach illustrated here [based on Crump (28)
and Kimmel and Gaylor (29)] is derived by modeling the data in the
observed range, selecting an incidence level within or near the observed
range (e.g., the effective dose to produce a 10% increased incidence of
response, the ED10), and determining the upper confidence limit on the
model. The upper confidence value corresponding to, for example, a 10%
excess in responseisused to derivethe BD,which is thelowerconfidence
limitondoseforthatlevelofexcessresponse,inthiscase,theLEDlo. The
reference dose (RfD) or RfD for developmental toxicity (RfDDT) esti-
mated by applying uncertainty factors (UF) to the BD would be greater
than or equal to the BD/UF.
140EVALUATING REPRODUCTIVE RISKS
doserangeformostquantalendpoints. Thus,theassump-
tion ofathreshold would notbe ofconcern in the choice of
the model because risk would not be extrapolated to low
levels ofexposure. If,however, there arebiological reasons
toincorporateparticularfactorsinthemodel(e.g.,intralit-
ter correlations), these should be included to account, as
much as possible, forvariability in the data.
EPA is currently conducting studies on the application
ofthe benchmark dose to actual data sets contributed by
several industrial and government laboratories. Informa-
tion gained from these efforts will be used towrite guide-
lines for using the benchmark dose approach in the risk
assessment process.
The qualitative and quantitative information on hazard
and dose-response, alongwith the NOAEL and RfD, are
compared to the human exposure estimates in the final
characterization of risk. Risk characterization is the
culmination ofthe risk assessment process, providing an
evaluation of the overall quality of the assessment and
describing risk in terms ofthe nature and extent ofharm.
Table 3 lists the essential components ofthe risk charac-
terization. A summary of the toxicity information,
together with its strengths and weaknesses and the
assumptions and uncertainties, is described, and the
NOAELs forthe various end points ofconcern (e.g., adult
male and female reproductive effects, developmental
effects, maternal toxicity), the RfD and RfDDT, the esti-
mates of human exposure, the margin of exposure (esti-
mated human exposure/NOAEL), the overall weight of
evidence, and the basis for the risk characterization are
given. Several risk characterizations may be appropriate,
e.g.,based onmaximal exposure, averageexposure, highly
exposed groups, or susceptible subpopulations. This infor-
mationisthen considered alongwitheconomic, technologi-
cal, social, and political factors in deciding howto manage
the attendant risks ofexposure in the population.
Research Needs in Reproductive Risk
Assessment
Research to improve risk assessment is needed in a
number of areas, as identified in the risk assessment
guidelines and outlined in Table 4. Several ofthese issues
have been explored in workshops supported and/or orga-
nized by EPA in which scientists deliberated to reach
consensus, where possible, and to identify further
lable 3. Components ofa risk characterization.
Characterization ofthe health-related data
Range ofeffective doses
No-observed-adverse-effect level (NOAEL) for reproductive and/or
developmental effects.






Basis for characterization, e.g., maximal exposure, average exposure,
highly exposed groups, sensitive populations
research needs. Forexample, aworkshop held in 1987(32)
focused ontherelationshipbetweenmaternalanddevelop-
mental toxicity and formed the basis for the current
position taken by EPA on this issue, i.e., developmental
toxicityinthepresenceofmaternaltoxicityisnotassumed
to be secondary to maternal toxicity (4). However, further
research efforts to elucidate the influence of maternal
toxicity on the developing offspring and vice versa are
needed. Similar issues concerning male and female
reproductive toxicityanditsrelationship to otherforms of
toxicity also need to be explored.
Another workshop focused on the use of one- versus
two-generation studies for reproductive toxicity evalua-
tion (33). Conclusions at this workshop supported the
continued use of two-generation reproduction studies to
thoroughly evaluate the potential reproductive effects of
an agent. Morecompletecharacterization and definition of
end points for female reproductive toxicity are needed, as
is information on the interrelationships among end points
of male reproductive toxicity. Such information could
improve the sensitivity and predictability of currently
used reproductive toxicity protocols.
In 1990, a workshop was held on the qualitative and
quantitative comparability ofhuman and animal develop-
mental neurotoxicants (11), at which experts reviewed the
human and animal data on known human developmental
neurotoxicants. The consensus ofopinion atthisworkshop
wasthatthegeneral types ofeffectsproduced byan agent
were similar in humans and in animal models and that
internal effective dose levels (when data were available)
were more similar across species than external exposure
levels. A great deal more work is needed on the effects of
agents ontheCNSandotherfunctionalsystems,including
the critical periods of exposure and improved testing
protocols.
Within the lastfewyears, amajorfocuswithin the EPA
hasbeen onthe developmentofquantitative approaches to
Table 4. Research needs in reproductive toxicity risk assessment.
Male and female reproductive toxicity
More completely characterize and define female reproductive end
points
Develop quantitative extrapolation between end points and function
(e.g., sperm count and fertility)
Better understand the relationship between reproductive effects and
other forms oftoxicity
Developmental toxicity
Further evaluate the relationship between maternal and developmen-
tal toxicity
Elucidate postnatal functional alterations and critical periods ofexpo-
sure
Evaluate the validity ofshort-term in vivo and in vitro tests
Both
Explore the interrelationships among end points
Delineate the mechanisms oftoxicity and pathogenesis
Develop comparative pharmacokinetic data
Further examine the threshold concept for dose-response relation-
ships
Develop improved mathematical models for dose-response modeling
Examine the effects of agents given by various routes ofexposure to
develop methodology for route-to-route extrapolation
Conduct epidemiology studies with more quantitative measures of
exposure
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developmental toxicity risk assessment, including the use
ofthe benchmark dose approach and development ofbio-
logically based dose-response models (34-36). For the
short term, we are studying the application ofthe bench-
mark dose methodology to actual data sets, and other
projects are focusing on the development of biologically
based dose-response models.
One aspect ofthisworkfocuses on the interrelationship
ofmultiple outcomesindevelopmental toxicitystudies. Ina
recent paper (37), we described the process of develop-
ment, as covered in segment II studies, as a continuum of
eventsleadingtoresorption ordeath, ortoaviablefetus at
term, and for that fetus, its malformation status and
weight. Although these manifestations are routinely
assessed in segment-II-type studies, the results are typ-
ically handled as independent experimental outcomes.
Assessment of multiple outcomes is complicated by the
presence ofcompetingrisks (e.g., implants that die during
organogenesis cannot go on to express malformations at
term). In addition, it is clear that there are correlations
between certain outcomes and that these can be incorpo-
rated into models that better characterize the nature of
the dose-response relationship. In this study, the joint
effect ofexposure on fetalweight and malformation status
was evaluated because these are two events that can be
quantified in an individual fetus. From this evaluation, it
was clear that malformed fetuses always tended to be
lowerinweightthan normal fetuses, eventhosewithinthe
same dose group.
Further work is underway on the development of a
modelincorporatingmalformations andfetalweightandis
the first effort to combine a continuous variable, fetal
weight,withabinaryvariable, thepresence orabsenceofa
malformation. This canbe accomplished byassumingthat
there is alatent, continuous variable ultimatelyinvolved in
the induction of a malformation and that a malformation
occurs when the value ofthe latent variable exceeds some
tolerance value for an individual fetus. Intralitter correla-
tions are also important in this relationship, such that
fetuses from light litters have a greater chance of being
malformed and fetuses that are lightwith respect to their
littermates are even more likely to be malformed. The
ultimate aim ofthis work is to extend the model to include
the conditional probability of being live (not resorbed or
dead) onfetalweightandmalformation status. Theadvan-
tages of this approach are that if all three outcomes are
unrelated, a combined analysiswould help ensure an over-
all effect was not missed, or, ifthey were correlated, that
theresultinganalysiswouldhavegreaterstatisticalpower.
Thus, an approach such as this could find immediate
application in dose-response modeling for risk assess-
ment.
Summary
It is important to keep in mind the complexity of the
sequence of events in the reproductive systems as both
testing and risk assessment approaches are reevaluted
and advances are made. Despite the problems ofextrapo-
latingfromanimal datato humans and offindingthe most
appropriate animal models, it is extremely important to
evaluate a broader range of reproductive effects than is
now the case in standard protocols. Several additions to
currentstandard protocols havebeen discussed thatcould
greatly improve the information available for interpreta-
tion. In addition, because ofthe fragmented way in which
toxicity testing is done overall, the age-related aspects of
various organ or system toxicities have often been over-
looked unless specific concerns are raised byobservations
in nonstandard laboratory animal studies or in exposed
human populations. A more logical approach to testing
might be to use the two-generation reproduction study
approach, with exposure beginning before mating and
continuing through pregnancy and lactation, and with
observation of various toxicities (e.g., reproductive tox-
icity, cancer, neurotoxicity, immunotoxicity, etc.) in the
resulting offspring. Thus, the two-generation study
design could be used or modified to evaluate the age-
related aspects of a number of organs or systems. An
addedbonus is thatcombining studies results inthe use of
fewer animals and lower costs fortestingthan conducting
individual studies and may also provide valuable insight
into mechanisms oftoxicity.
The views expressed in this paper are those ofthe author and do not
necessarily reflect the views or policies of the U.S. Environmental
Protection Agency.
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